Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors

Molecular Pharmacology

Volumn 64, Issue 1, 2003, Pages 180-190

  Tränkle, Christian ^a   Weyand, Oliver ^a   Voigtländer, Uta ^a   Mynett, Anita ^b   Lazareno, Sebastian ^c   Birdsall, Nigel J M ^b   Mohr, Klaus ^a  

^a UNIVERSITY OF BONN   (Germany)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,6 HEXAMETHYLENEBIS[DIMETHYL(3 PHTHALIMIDOPROPYL)AMMONIUM BROMIDE]; 4,4' BIS[(2,6 DICHLOROBENZYLOXYIMINO)METHYL] 1,1' PROPANE 1,3 DIYLBISPYRIDINIUM DIBROMIDE; BROMINE DERIVATIVE; METHYLSCOPOLAMINE; MUSCARINIC M2 RECEPTOR; N,N' BIS[3 (1,3 DIHYDRO 1,3 DIOXO 5 METHYL 2H ISOINDOL 2 YL)PROPYL] N,N,N',N' TETRAMETHYL 1,6 HEXANEDIAMINIUM DIIODIDE; RADIOLIGAND; TACRINE; TRITIUM; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CONTROLLED STUDY; DISSOCIATION; DRUG BINDING SITE; DRUG POTENCY; DRUG RECEPTOR BINDING; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; CHO CELLS; CRICETINAE; DRUG INTERACTIONS; KINETICS; LIGANDS; N-METHYLSCOPOLAMINE; PHTHALIMIDES; PYRIDINIUM COMPOUNDS; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTOR, MUSCARINIC M2; RECEPTORS, MUSCARINIC; TACRINE; TRITIUM;

EID: 0038575799     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.1.180     Document Type: Article

References (42)

1. Birdsall NJM, Farries T, Gharagozloo P, Kobayashi S, Kuonen D, Lazareno S, Popham A, and Sugimoto M (1997) Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes. Life Sci 60:1047-1052.
2. Birdsall NJM, Farries T, Gharagozloo P, Kobayashi S, Lazareno S, and Sugimoto M (1999) Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: functional studies. Mol Pharmacol 55:778-786.
3. Birdsall NJM, Lazareno S, and Matsui H (1996) Allosteric regulation of muscarinic receptors. Prog Brain Res 109:147-151.
4. Buller S, Zlotos DP, Mohr K, and Ellis J (2002) Allosteric site on muscarinic acetylcholine receptors: a single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V derivatives and alkane-bisammonium ligands. Mol Pharmacol 61:160-168.
5. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
6. Clark AL and Mitchelson F (1976) The inhibitory effect of gallamine on muscarinic receptors. Br J Pharmacol 58:323-331.
7. DeBlasi A, O'Reilly K, and Motulsky HJ (1989) Calculating receptor number from binding experiments using same compound as radioligand and competitor. Trends Pharmacol Sci 10:227-229.
8. Ehlert FJ (1988) Estimation ot the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 35:187-194.
9. Ellis J (1997) Allosteric binding sites on muscarinic receptors. Drug Dev Res 40:193-204.
10. Ellis J, Huyler J, and Brann M (1991) Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes. Biochem Pharmacol 42:1927-1932.
11. Ellis J and Seidenberg M (1992) Two allosteric modulators interact at a common site on cardiac muscarinic receptors. Mol Pharmacol 42:638-641.
12. Ellis J and Seidenberg M (2000) Interactions of alcuronium, TMB-8 and other allosteric ligands with muscarinic acetylcholine receptors: studies with chimeric receptors. Mol Pharmacol 58:1451-1460.
13. Ellis J, Seidenberg M, and Brann MR (1993) Use of chimeric muscarinic receptors to investigate epitopes involved in allosteric interactions. Mol Pharmacol 44:583-588.
14. Gharagozloo P, Lazareno S, Miyauchi M, Popham A, and Birdsall NJM (2002) Substituted pentacyclic carbazolones as novel muscarinic allosteric agents: synthesis and structure-affinity and cooperativity relationships. J Med Chem 45:1259-1274.
15. Holzgrabe U and Mohr K (1998) Allosteric modulators of ligand binding to muscarinic acetylcholine receptors. Drug Disc Today 3:214-222.
16. Jakubík J, Bačáková L, El-Fakahany EE, and Tuček S (1997) Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 52:172-179.
17. 2 receptors in guinea pig atria. Eur J Pharmacol 416:235-244.
18. 3H-N-methylscopolamine and acetylcholine at M1-M4 muscarinic receptors. Life Sci 64:519-526.
19. Lazareno S and Birdsall NJM (1995) Detection, quantitation and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362-378.
20. Lazareno S, Gharagozloo P, Kuonen D, Popham A, and Birdsall NJM (1998) Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol Pharmacol 53:573-589.
21. 3H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. Mol Pharmacol 58:194-207.
22. Lazareno S, Popham A, and Birdsall NJM (2002) Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol Pharmacol 62:1492-1505.
23. 2 muscarinic acetylcholine receptor. Mol Pharmacol 45:983-990.
24. Lu ZL, Saldanha JW, and Hulme EC (2002) Seven-transmembrane receptors: crystals clarify. Trends Pharmacol Sci 23:140-146.
25. Lüllmann H, Ohnesorge FK, Schauwecker GC, and Wassermann O (1969) Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bis-ammonium compounds. Eur J Pharmacol 6:241-247.
26. Matsui H, Lazareno S, and Birdsall NJM (1996) Probing the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. Mol Pharmacol 47:88-98.
27. Pedder EK, Eveleigh P, Poyner D, Hulme EC, and Birdsall NJM (1991) Modulation of the structure-binding relationships of antagonists for muscarinic acetylcholine receptor subtypes. Br J Pharmacol 103:1561-1567.
28. 1 muscarinic receptors. Mol Pharmacol 35:652-660.
29. 2 receptors as deduced from buffer-dependent potency shifts. Naunyn Schmiedeberg's Arch Pharmacol 362:512-519.
30. Soudijn WS, Van Wijngaarden I, and IJzermann AP (2001) Allosteric modulation of G protein coupled receptors. Expert Opin Ther Patents 11:1889-1904.
31. Stockton JM, Birdsall NJM, Burgen ASV, and Hulme EC (1983) Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 23:551-557.
32. 2 receptor binding of the selective antagonist AF-DX 384: possible involvement of the common allosteric site. Mol Pharmacol 53:304-312.
33. Tränkle C, Kostenis E, Burgmer U, and Mohr K (1996) Search for lead structures to develop new allosteric modulators of muscarinic receptors. J Pharmacol Exp Ther 279:926-933.
34. 2 receptors. Mol Pharmacol 54:139-145.
35. 2 receptors. Mol Pharmacol 51:674-682.
36. 2 receptors. Br J Pharmacol 129:248P.
37. 2 muscarinic acetylcholine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 361(Suppl):R23.
38. 2 receptors. Mol Pharmacol 56:962-965.
39. Tuček S and Proška J (1995) Allosteric modulation of muscarinic acetylcholine receptors. Trends Pharmacol Sci 16:205-212.
40. Waelbroeck M (1994) Identification of drugs competing with d-tubocurarine for an allosteric site on cardiac muscarinic receptors. Mol Pharmacol 46:685-692.
41. 2 muscarinic receptors. Life Sci 68:2621.
42. Zahn K, Eckstein N, Tränkle C, Sadeé W, and Mohr K (2002) Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. J Pharmacol Exp Ther 301:720-728.